Navigation Links
Cells in Good Cheer With Vitamin C

Vitamin C has long been known to give a boost to the body’s immunity especially in fighting common cold, and in ensuring good health//. Now, a Christchurch researcher has delved into the scientific reasons behind the blessing of Vitamin C, demonstrating that apart from maintaining the body’s cells, Vitamin C may also help fight cancer.

Margaret Vissers from the Free Radical Research Group, along with a team from the Angiogenesis Research Group at the Christchurch School of Medicine and Health Sciences, showed that Vitamin C has an important part to play in all healthy cells. Infact it impacts cell activity positively.

Dr Vissers' work, sponsored by the Health Research Council, has demonstrated that key enzymes in the cell require Vitamin C to kick start; low levels of the vitamin means that enzymes may not be able to do their work. The enzymes influence cell growth, death and the response to stress.

Dr Vissers said, "This also means that a lack of vitamin C increases tumor growth and prevents effective treatment. It follows that restoring vitamin C to normal levels means less tumor growth and more successful chemotherapy."
SA
'"/>




Page: 1

Related medicine news :

1. Blood Cells Capable of Regenerating Liver
2. White Cells Count Can Predict Heart Attack Death Risk
3. Gene Therapy Destroys Pancreatic Cancer Cells
4. Stem Cells Have Few Mutations
5. Heart may pull Cells from Body to Self-repair
6. Cells critical for asthma development found
7. Vitamin D Wipes out Cancer Cells
8. Bone Marrow Cells Help Heart Attack Patients
9. Islet Cells May Lead to Diabetes CureChildren
10. Stem Cells Found To Offer Promise For Hair Growth
11. Bone Marrow Cells Could Yield A New Lease of Life
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cells Good Cheer With Vitamin

(Date:5/12/2008)... to have committed patent and ...2 /PRNewswire-FirstCall/ -- Mannatech,Incorporate...r of dietary,supplements and skin care solutions, ...orthern District of Texas found that Glycoproducts...Mannatech,s patent and,trademark relating to Ambro...
(Date:5/12/2008)...Assists Removal of 975 Cardiac ...12 /PRNewswire-FirstCall/ -- Spectranetics,Corpora...reviewed study,demonstrates Spectranetics, excimer...al of pacing and defibrillator leads. The study, "...e with Transvenous Lead,Extraction: Outcomes and C...
(Date:5/12/2008)...g been known that embryonic stem cells have the ab...cells, the exact mechanism as to how this occurs h...ers at the Hebrew University of Jerusalem and else... process, resolving a long-standing question as to...through selective activation or selective repressi...
(Date:5/12/2008)...tCall/ -- ULURU Inc. (Amex: ULU ),today reported ...h 31,2008., For the quarter ended March 31, 2008... was $1,815,000, or $0.03 per share, compared to a... corresponding period in 2007.,The first quarter 2...$497,000, which included stock option expense, amo...
Breaking Medicine News(10 mins):Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 2Health News:Jury Validates Key Mannatech Technology Patents Involving Its Ambrotose(R) Glyconutrient Products 3Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 2Health News:Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal 3Health News:How embryonic stem cells develop into tissue-specific cells demonstrated 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 2Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 3Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 4Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 5Health News:ULURU Inc. Reports First Quarter 2008 Financial Results 6
...oman’s reproductive years, usually occurs around a...xperience //early menopause. Early menopause can b...ealth problems, including osteoporosis and cardiov...of Mayo Clinic Women’s HealthSource describes type...
...fits of mammogram screenings because the results a... study by //Yale Public Health researchers in the ... To help reduce death and disability from breast ...of cancer death in American women, current guideli...
...rsity scientists led by Thomas Carpenter, findings...lements for girls, as their effects// would be see...sts carried out a trial on 120 girls aged 8 to 14 ...ium supplements of 300 mg dose and others on a pla...
...ore dispensaries by 2010 to provide better healthc... said Thursday.// She said 365 dispensaries were ... would be set up soon to "enable the common men av...heir doorsteps". The chief minister said her gov...
Other Medicine News:Health News:Inadequate Communication Reduces Benefits of Mammogram Screening for Black Women 2
(Date:5/8/2008)...irstCall/ -- AstraZeneca (NYSE:,AZN) today announc...cation,(sNDA) to the U.S. Food and Drug Administra...e) Extended-Release Tablets to seek approval for t..., including maintenance of,antianxiety effect. It ...atypical antipsychotic medicine in GAD. The submis...
(Date:5/8/2008)... -- Go Healthy (Pink Sheets: GOHE),announces the i...rade (R),in three medical settings with an expecte...ers around the country. Dr. William Bryan of the S... in the Texas Medical Center,will coordinate one c...sician for the Houston Astros and the former Medic...
(Date:5/7/2008)...nduction Dosing Regimen, SEATTLE, May 7 /PRNewswi...daq: TRBN ) today announced that its partner, Wye...E ), has commenced patient dosing in the next,Phas...eumatoid arthritis,(RA). In collaboration with Tru... SBI-087 and other CD20-directed products., The r...
(Date:5/7/2008)...ll/ -- Shire plc (LSE: SHP,Nasdaq: SHPGY), the gl...nounced findings from a new data analysis that was...AYTRANA(TM) (methylphenidate transdermal,system) b...ntion Deficit,Hyperactivity Disorder (ADHD). The f... has an established safety profile and effectively...
Breaking Medicine Technology:AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines 8Go Healthy Initiates Additional Clinical Tests on Cholesterade 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 2Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 3Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 2New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 3New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 4New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 5New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 6New Analysis in Boys and Girls Shows the ADHD Patch, DAYTRANA(TM) (methylphenidate transdermal system), Offered ADHD Symptom Control for 12 Months 7Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 767 1Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates 767 2Hemoglobin uncovered 1126 1Hemoglobin uncovered 1126 2Ripe fruit preferred 1124 1Ripe fruit preferred 1124 2Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 1Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 2Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 3Virginia Commonwealth University to Study Genomics Based Diagnostic Test 3A 5625 4
...SIGA Technologies, Inc.,(NASDAQ: SIGA) announced t...guinea pig trial of its lead Lassa fever virus dru...ty Level 4 conditions at,the U.S. Army Medical Res...by Dr. Kathleen Cashman under the supervision of D...hemorrhagic fever,viruses at USAMRIID for over 12 ...
...drug withdrawal, CHICAGO, May 15, 2007 /PRNewswire... and physicians commissioned by the National,Heada... shows that,20 percent of migraine patients are cu...hat contain barbiturates or opioids and have,not b...ion for the,relief of migraines. , Migraines affec...
Other Medicine Technology:SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 2SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 3SIGA Passes First Hurdle with Lassa Fever Antiviral ST-193 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 2Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 3Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 4Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 5Survey: Migraine Patients Taking Potentially Addictive Barbiturate,or Opioid Medications Not Approved by FDA as Migraine Treatments 6
... Stripe S600 ranks among Zebra's most popular prin...ount on consistent, reliable performance. The S600... real-time clock and Zebra Printer Management for ...an accommodate a full-sized roll of media within t...
...lt on the solid, tested XiIIIPlus platform, the R1...d level of on-demand printing flexibility in tag p...r seamless integration into enterprise systems, au...ultiple power levels, statistics tracking, easier ...
The industrys first 600 dpi printer the 96XiIII is unmatched for printing large amounts of bar code, text and graphics information in limited label space. This printer is ideal for applications that
The 105SL is the newest member of the Zebra S Series™, and its also the fastest, combining enhanced memory and processing capacity with rugged and reliable all-metal construction. Based on a pro
Medicine Products: